Gene/Protein Disease Symptom Drug Enzyme Compound
Pivot Concepts:   Target Concepts:
Query: UNIPROT:P04155 (pS2)
 1,234 document(s) hit in 31,850,051 MEDLINE articles (0.00 seconds)

Estrogen and progesterone receptors (ER and PR) on 48 surgically removed breast cancers were evaluated by three methods: immunoenzymatic (ER/PR-EIA), immunohistochemical in frozen sections (ER/PR-ICA), and immunohistochemical in paraffin sections (ER/PR-PAR). The monoclonal antibodies H222 and KD68 were used for immunohistochemical detection of ER and PR, respectively. Immunohistochemical stains for pS2, an estrogen-regulated protein, were also done for compatibility with previous ER/PR-PAR studies. We assessed concordance with chi-square and Pearson's correlation coefficient. We concluded that ER/PR-PAR is the least sensitive of the three assays (90.9% ER, 88.5% PR) and, until appropriate technical and clinical validation is achieved, should not be used as a first-line assay. Also, because of this lower sensitivity, we recommended that pS2 evaluation always accompany ER/PR-PAR to facilitate distinction between clinical negatives and those due to irretrievably lost immunoreactivity. We also conclude that ER/PR-ICA is a good semi-quantitative method that, in combination with ER/PR-EIA, most accurately assesses receptor status.
 ...
PMID:Immunohistochemical detection of sex steroid receptors in breast cancer using routine paraffin sections: comparison with frozen sections and enzyme immunoassay. 782 84